| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial |
| Creator | Rouzier et al. |
| Author | Roman Rouzier |
| Author | Sébastien Gouy |
| Author | Frédéric Selle |
| Author | Eric Lambaudie |
| Author | Anne Floquet |
| Author | Virginie Fourchotte |
| Author | Christophe Pomel |
| Author | Pierre-Emmanuel Colombo |
| Author | Elsa Kalbacher |
| Author | Sandrine Martin-Francoise |
| Author | Raffaele Fauvet |
| Author | Philippe Follana |
| Author | Anne Lesoin |
| Author | Fabrice Lecuru |
| Author | Youssef Ghazi |
| Author | Julien Dupin |
| Author | Elisabeth Chereau |
| Author | Sarah Zohar |
| Author | Paul Cottu |
| Author | Florence Joly |
| Abstract | AIM: To investigate whether adding bevacizumab to neoadjuvant carboplatin-paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate (CRR) at interval debulking surgery (IDS), in patients with initially unresectable International Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocarcinoma. METHODS: Multicentre, open-label, non-comparative phase II study. Ninety-five patients randomised (2:1) to receive four cycles of neoadjuvant CP ±3 concomitant cycles of bevacizumab 15 mg/kg (BCP) followed by IDS. Primary objective is to evaluate the CRR at IDS in the BCP group (reference CRR rate defined as 45% CRR). A stopping rule based on bevacizumab-related adverse events (AEs) of special interest was implemented. RESULTS: In the BCP group (N = 58), IDS was performed in 40 (69%) patients, of whom 85% had a complete resection. The CRR of this group was therefore 58.6% (34 patients), statistically over pre-defined 45%. The CRR in the CP group was 51.4%: 22 (60%) patients underwent IDS (85% had a complete resection). Grade ?3 adverse events occurred in 62% of the BCP-treated patients and 63% of the CP-treated patients: mainly blood and lymphatic, gastrointestinal and vascular disorders, without more toxicity with BCP. Postoperative complications (mainly wound, infectious and gastrointestinal complications) occurred in 28% and 36% of the patients, respectively. The pre-specified safety stopping rule was not reached. CONCLUSION: The primary objective was met as the CRR with BCP was significantly higher than the reference rate. Bevacizumab may be safely added to a preoperative program in patients deemed non-optimally resectable, whatever the final surgical decision. Bevacizumab's role in this setting should be further investigated. |
| Publication | European Journal of Cancer (Oxford, England: 1990) |
| Volume | 70 |
| Pages | 133-142 |
| Date | 01 2017 |
| Journal Abbr | Eur. J. Cancer |
| Language | eng |
| DOI | 10.1016/j.ejca.2016.09.036 |
| ISSN | 1879-0852 |
| Short Title | Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer |
| Library Catalog | PubMed |
| Extra | PMID: 27914243 |
| Tags | Adenocarcinoma, Adult, Aged, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carboplatin, clinic, Cytoreduction Surgical Procedures, Female, Humans, Interval debulking surgery, Middle Aged, Neoadjuvant chemotherapy, Neoadjuvant Therapy, Ovarian Neoplasms, Paclitaxel, Peritoneal Neoplasms |
| Date Added | 2019/05/31 - 16:39:58 |
| Date Modified | 2019/05/31 - 16:40:10 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
